nach oben

28.03.2024 | REVIEW

Symmetrical Drug-Related Intertriginous and Flexural Exanthem-Like Eruption Post-COVID-19 Vaccination: A Case Report and Review of the Literature

verfasst von: Cagdas Boyvadoglu, Salih Levent Cinar

Erschienen in: Current Dermatology Reports

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

SDRIFE (Symmetrical drug-related intertriginous and flexural exanthema) is type IV hypersensitivity drug-related skin eruption. Numerous drugs have previously been associated with SDRIFE; however few cases associated with the coronavirus disease 2019 (COVID-19) vaccine have been reported. Here, we present a case in which SDRIFE was generated following administration of the CoronaVacTM (SinoVac Biotech Corporation) vaccine. A literature review was also conducted to summarize the various cases of SDRIFE induced by the coronavirus disease 2019 (COVID-19) vaccine.

Recent Findings

SDRIFE is a rare complication of COVID-19 vaccines. Here, we reviewed all 14 cases reported in the literature, along with our own case. Three cases, including ours, have been reported with the CoronaVacTM vaccine, a purified, inactivated antigen vaccine produced by the SinoVac Biotech Corporation.

Summary

SDRIFE-like eruptions are thought to constitute a delayed type IV immune response to COVID-19 vaccines. However, further studies are required to determine the possible underlying mechanisms involved. The use of COVID-19 vaccines is affecting an increasing number of people worldwide. Therefore, clinicians should be informed of any adverse reactions that may occur. Knowing these reactions can help us illuminate the possible mechanisms of the COVID-19 and other COVID-19 vaccines.

Winnicki M, Shear NH. A systematic approach to systemic contact dermatitis and symmetric drug-related intertriginous and flexural exanthema (SDRIFE): a closer look at these conditions and an approach to intertriginous eruptions. Am J Clin Dermatol. 2011;12(3):171–80. https://doi.org/10.2165/11539080-000000000-00000.CrossRefPubMed

•• Orenay OM, Balta I, Yigit D, Eksioglu M. Systemic drug-related intertriginous and flexural exanthema like eruption after CoronaVac vaccine. J Eur Acad Dermatol Venereol. 2021;35(10):e634–5. https://doi.org/10.1111/jdv.17454. This article is important because it is the first to report the development of SDRIFE-like eruption after COVID vaccination.CrossRefPubMedPubMedCentral

Hai J, Shawa H, Kim-Lim P, et al. Systemic drug-related intertriginous and flexural exanthema induced by the Pfizer-BioNTech COVID-19 vaccine: A report of 2 cases. JAAD Case Rep. 2021;18:57–60. https://doi.org/10.1016/j.jdcr.2021.10.016.CrossRefPubMedPubMedCentral

Bellinato F, Maurelli M, Gisondi P, Girolomoni G. Cutaneous adverse reactions associated with SARS-CoV-2 vaccines. J Clin Med. 2021;10(22):5344. https://doi.org/10.3390/jcm10225344. Published 2021 Nov 16.CrossRefPubMedPubMedCentral

Lim PN, Wylie G. Symmetrical drug-related intertriginous and flexural exanthema like eruption associated with COVID-19 vaccination. Clin Exp Dermatol. 2022;47(1):175–6. https://doi.org/10.1111/ced.14898.CrossRefPubMed

Hong JK, Shin SH, Yoo KH, Li K, Seo SJ. Symmetric drug-related intertriginous and flexural exanthema-like eruption related to coronavirus disease 2019 vaccine. Contact Dermatitis. 2022;87(1):91–3. https://doi.org/10.1111/cod.14092.CrossRefPubMedPubMedCentral

Manaa A, Ziv M, Krausz J, Dodiuk-Gad RP. A case of symmetrical drug-related intertriginous and flexural exanthema-like eruption associated with Pfizer COVID-19 vaccination. Dermatol Ther. 2022;35(7):e15546. https://doi.org/10.1111/dth.15546.CrossRefPubMedPubMedCentral

Sandhu J, Katha M, Gupta SK. Covishield™ (ChAdOx1 nCoV-19) Vaccine-Induced Systemic Drug-Related Intertriginous and Flexural Exanthema in a Young Girl: A Case Report and Literature Review. Indian J Dermatol. 2022;67(6):783–5. https://doi.org/10.4103/ijd.ijd_511_22.CrossRefPubMedPubMedCentral

Lahouel I, Ben Salah N, Ben Fadhel N, et al. Symmetrical drug-related intertriginous and flexural exanthema-like eruption after COVID-19 vaccine. J Eur Acad Dermatol Venereol. 2022;36(8):e597–9. https://doi.org/10.1111/jdv.18108.CrossRefPubMedPubMedCentral

10.

Camela E, Scalvenzi M, Megna M, et al. Reply to “A case of symmetrical drug-related intertriginous and flexural exanthema-like eruption associated with Pfizer COVID-19 vaccination” by Manaa et al. Dermatol Ther. 2022;35(12):e15881. https://doi.org/10.1111/dth.15881.CrossRefPubMed

11.

Çakıcı ÖA, Güder S, Salman A, Ergun T. Symmetrical drug-related intertriginous and flexural exanthema-like eruption: An addition to the spectrum of coronavirus disease 2019-related cutaneous findings. Indian J Dermatol Venereol Leprol. 2022;88(6):814–6. https://doi.org/10.25259/IJDVL_165_2022.CrossRefPubMed

12.

Andersen KE, Hjorth N, Menné T. The baboon syndrome: systemically induced allergic contact dermatitis. Contact Dermatitis. 1984;10(2):97–100. https://doi.org/10.1111/j.1600-0536.1984.tb00343.x.CrossRefPubMed

13.

Häusermann P, Harr T, Bircher AJ. Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome? Contact Dermatitis. 2004;51(5–6):297–310. https://doi.org/10.1111/j.0105-1873.2004.00445.x.CrossRefPubMed

14.

• Harbaoui S, Litaiem N. Symmetrical Drug-Related Intertriginous and Flexural Exanthema. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022. This book provides up-to-date and detailed information on the etiology, epidemiology, pathophysiology, histopathology, evaluation, treatment and management, differential diagnosis, prognosis, complications, and patient education in symmetrically drug-related intertriginous and flexural exanthema.

15.

Schuler AM, Smith EH, Chaudet KM, et al. Symmetric drug-related intertriginous and flexural exanthema: Clinicopathologic study of 19 cases and review of literature. J Cutan Pathol. 2021;48(12):1471–9. https://doi.org/10.1111/cup.14090.CrossRefPubMed

16.

Heck J, Stichtenoth DO, Mettin R, Jöckel J, Bickel C, Krichevsky B. Remdesivir-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE)? A case report with review of the literature. Eur J Clin Pharmacol. 2021;77(1):141–4. https://doi.org/10.1007/s00228-020-02955-4.CrossRefPubMed

17.

Keshavamurthy C, Fibeger E, Virata A, Bansal P. Symmetrical drug-related intertriginous and flexural exanthema (Baboon syndrome) associated with Infliximab: a case-based review. Symmetrical drug-related intertriginous and flexural exanthema (Baboon syndrome) associated with Infliximab: a case-based review. ARP Rheumatol. 2022;1(4):322–7.PubMed

18.

Bonamigo RR, Bottega GB, Staub FL, Almeida RO, Werka HMG. Bullous SDRIFE and Covid-19. Int J Dermatol. 2022;61(3):372–4. https://doi.org/10.1111/ijd.16012.CrossRefPubMed

19.

Chicharro P, Rodríguez-Jiménez P, Muñoz-Aceituno E, De Argila D, Muñoz-Hernández P, Llamas-Velasco M. SDRIFE-like rash associated with COVID-19, clinicopathological correlation. Australas J Dermatol. 2021;62(1):88–9. https://doi.org/10.1111/ajd.13444.CrossRefPubMed

20.

Bevilaqua M, Ribolli GB, Luzzatto L, Fernandes JC, Pasqualotto AC, Bonamigo RR. SDRIFE-like rash in COVID-19 patient: drug reaction or another cutaneous manifestation of SARS-CoV-2? Int J Dermatol. 2021;60(7):884–5. https://doi.org/10.1111/ijd.15537.CrossRefPubMedPubMedCentral

21.

Athira R, Hamsa L, Thomas N, Zacharias R. SDRIFE-Like Rash With COVID - 19. Indian Pediatr. 2022;59(2):168. https://doi.org/10.1007/s13312-022-2451-3.CrossRefPubMed

22.

Zenarola P, Gimma A, Lomuto M. Systemic contact dermatitis from thimerosal. Contact Dermatitis. 1995;32(2):107–8. https://doi.org/10.1111/j.1600-0536.1995.tb00756.x.CrossRefPubMed

Titel: Symmetrical Drug-Related Intertriginous and Flexural Exanthem-Like Eruption Post-COVID-19 Vaccination: A Case Report and Review of the Literature
verfasst von: Cagdas Boyvadoglu
Salih Levent Cinar
Publikationsdatum: 28.03.2024
Verlag: Springer US
Erschienen in: Current Dermatology Reports
Elektronische ISSN: 2162-4933
DOI: https://doi.org/10.1007/s13671-024-00426-y

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Isotretinoin: Risiko für schwere Laboranomalien „marginal erhöht“

08.05.2024 Akne Nachrichten

Die Aknetherapie mit Isotretinoin kann einen Anstieg von Leberenzymen und Blutfetten verursachen. Das Risiko für schwere Störungen ist laut einer Forschungsgruppe der Universität Lübeck aber nur marginal erhöht und auf einen engen Zeitraum konzentriert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen